Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population

Figures

• 

  Fig. 1. Study design. Data source: Optum’s de-identified Clinformatics® Data Mart Database, consisting of patients with AF, from January 1, 2012, to September 30, 2021. AF atrial fibrillation; GPI generic product identifier; ICD-9-CM International Classification of Diseases, Ninth Revision, Clinical Modification; ICD-10-CM International Classification of Diseases, Tenth Revision, Clinical Modification; NVAF non-valvular atrial fibrillation; HRU healthcare resource use1GPI drug codes were used to identify pharmacy claims for rivaroxaban and warfarin2Treatment discontinuation is defined as a gap in days of supply (i.e., > 30 days) between the end of a dispensing (based on days of supply) and the next fill or between the end of the last dispensing and the end of data3AF was identified with the following ICD-9-CM codes: 427.31, or ICD-10-CM: I48.0, I48.1x, I48.2x, I48.914Diabetes was identified as ≥ 2 diagnosis of diabetes (ICD-9-CM codes: 250.x, or ICD-10-CM codes: E10.x–E13.x) at least 30 days apart during the baseline period or on the index date, or ≥ 1 dispensing for an antidiabetic medication and ≥ 1 diagnosis of diabetes during the baseline period or on the index date

• 

  Fig. 2. Patient disposition. Data Source: Optum’s de-identified Clinformatics® Data Mart Database, consisting of patients with NVAF and diabetes, from January 1, 2012, to September 30, 2021. AF atrial fibrillation; GPI generic product identifier; ICD-9-CM International Classification of Diseases, Ninth Revision, Clinical Modification; ICD-10-CM International Classification of Diseases, Tenth Revision, Clinical Modification; NVAF non-valvular atrial fibrillation; VTE venous thromboembolism1Baseline period was defined as the 12 months prior to the index date (excluding the index date)2AF was identified with the following codes: ICD-9-CM: 427.31; ICD-10-CM: I48.0, I48.1x, I48.2x, I48.913Diabetes was identified with the following codes ICD-9-CM: 250.x; ICD-10-CM: E10.x, E11.x, E12.x, E13.x

• 

  Fig. 3. Healthcare Resource Utilization among weighted rivaroxaban and warfarin cohorts, up to 12 months of follow-up1. CI confidence intervals; ER emergency room; OP outpatient; *p < 0.001; 1The observation period spans from the index date up to the treatment discontinuation, a switch to/addition of another oral anticoagulant, 12 months post-index, death, end of eligibility, or end of data availability, whichever occurs first2Rate ratios are calculated from Poisson regression models3CI and p values are generated using a non-parametric bootstrap procedure with 499 replications

• 

  Fig. 4. Healthcare Costs among weighted rivaroxaban and warfarin cohorts, up to 12 months of follow-up1. CI confidence intervals; ER emergency room; OP outpatient; PPY per patient-year1The observation period spans from the index date up to the treatment discontinuation, a switch to/addition of another oral anticoagulant, 12 months post-index, death, end of eligibility, or end of data availability, whichever occurs first2CI and p values are generated using a non-parametric bootstrap procedure with 499 replications